Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Incyte

Is Incyte Stock Underperforming the Nasdaq?

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers

Dow Jones tech giant Intel led the S&P 500 Monday, and kept running late. Apple chipmakers Qorvo and Skyworks sold off on iPhone 16 concerns.

Investors Business Daily

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Investors Business Daily

2 Best Growth Stocks to Buy with $1,000 Right Now

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

StockNews.com

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Investors Business Daily

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review

The major indexes retreated for most of the week on banking fears, but rebounded Friday on a strong jobs report and bank stocks roaring back.

Investors Business Daily

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales

Incyte stock plummeted Tuesday as seasonality hacked at first-quarter revenue and profit with notable sales misses from Jakafi and Opzelura.

Investors Business Daily

S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday

Micron Technology and Charles Schwab were among the top S&P 500 stock performers on Monday. Expedia was a notable loser.

Investors Business Daily

Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker

Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi.

Investors Business Daily

Top-Notch Medical Stocks Incyte, Haemonetics Beat — And Shares Crumbled

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics tumbled on its beat.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Investors Business Daily

9 Companies' Profit Set To Triple While S&P 500 In Free Fall

You might think fourth quarter earnings reports are ugly if you're just looking at the S&P 500. More than a few stocks buck the trend.

Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Investors Business Daily

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.

Investors Business Daily

Use This IBD Rating To Find Stock Market Leaders By Tracking Institutional Demand

Track institutional demand to find high-quality growth stocks approaching potential buy points.

Investors Business Daily

IBD Stock Of The Day Incyte Nears Buy Point After Winning A First-Ever Approval

IBD Stock Of The Day Incyte just won U.S. approval for a new skin treatment, leading Incyte stock to flirt with a breakout.

StockNews.com

3 Stocks the World's Greatest Investors Are Buying up Right Now

Skyrocketing inflation, the Fed’s aggressive interest rate hikes, and growing recession fears have kept the stock market under tremendous pressure lately. Amid the market’s downtrend, the world’s renowned investors are scooping up quality stocks Occidental Petroleum (OXY), Amazon.com (AMZN), and Incyte (INCY). Continue reading….

Benzinga

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

Image sourced from Shutterstock

Benzinga

Twitter And 3 Other Stocks Insiders Are Selling

US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

1 2 3

People

Jerome Powell

3,213 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.